End Stage Liver DIsease
96
14
18
39
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.3%
8 terminated out of 96 trials
83.0%
-3.6% vs benchmark
10%
10 trials in Phase 3/4
26%
10 of 39 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 39 completed trials
Clinical Trials (96)
Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease
Adverse Outcomes and Mortality in Liver Transplant
Evaluating Novel Scoring Systems to Predict Outcomes in Acute-on-Chronic Liver Failure
Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation
Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant
Functional Assessment in Liver Transplantation
Angiotensin 2 for AKI After OLT
Longitudinal Study of Mitochondrial Hepatopathies
Effect of Preoperative Oral Carbohydrate Loading on Postoperative Outcomes in Liver Transplant Patients
VitaSmart HOPE System: Bridge to HOPE Registry
Disparities Among Liver Transplant Patients
Immune Tolerance Induction After Liver Transplantation
Quantitative Liver Function Tests Using Cholates
Tocotrienol Against the Progression of End Stage Liver Disease
Single-Cell and Spatial Transcriptomics Analysis of Steatotic Donor Liver Susceptibility to Post-Transplant Injury
Functional Assessment in Liver Transplantation
Pilot Study of the Liver Live Donor Champion Program
Growth Hormone in Decompensated Liver Cirrhosis
Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)
A Study of SIPLIZUMAB in AILD and LT Patients